Thank you for that.
I appreciate your remarks about the Cochrane Collaboration and what they determined about the increased risk, or at least when the studies were funded solely by pharmaceutical companies that there was more likelihood they would be more positive in the conclusions.
I wanted to ask you, sir, and our other witnesses here, about a point that Elaine Gibson raised. I'm sorry she's not here to develop this. That was the question about expanding the application to all holders of therapeutic products, rather than only the sellers. Is that an issue?
Maybe I'll turn to Mr. Herder. Is that something on your radar? Do you think that's a point we should follow up on?